Form 4: Alaunos Therapeutics VP Acquires Stock Options
SEC Form 4 Filing
Ferdinand Groenewald, VP of Finance at Alaunos Therapeutics, acquired stock options on March 29, 2025.
Summary
- Ferdinand Groenewald, VP of Finance at Alaunos Therapeutics, filed a Form 4 on March 31, 2025.
- The filing reports a transaction on March 29, 2025, where Groenewald acquired employee stock options for 3,000 shares of common stock at an exercise price of $1.46.
- The options vest in equal quarterly installments over four years, starting June 29, 2025, contingent upon continued service.
- Following the transaction, Groenewald directly owns options for 3,000 shares.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a routine filing of stock option grants. The executive's acquisition of options can be seen as a mildly positive signal.
Positives
- The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/29/2025 | Date of the stock option transaction. |
| 06/29/2025 | First vesting date for the stock options. |
| 03/28/2035 | Expiration date of the stock options. |
| 03/31/2025 | Date of Form 4 filing. |
Keywords
Form 4, Alaunos Therapeutics, Stock Options, Beneficial Ownership, TCRT, Groenewald, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.